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Abstract
Background: In the absence of an effective vaccine against HIV-1, the scientific community is presented with the
challenge of developing alternative methods to curb its spread. Due to the complexity of the disease, however, our
ability to predict the impact of various prevention and treatment strategies is limited. While ART has been widely
accepted as the gold standard of modern care, its timing is debated.
Objectives: To evaluate the impact of medical interventions at the level of individuals on the spread of infection
across the whole population. Specifically, we investigate the impact of ART initiation timing on HIV-1 spread in an
MSM (Men who have Sex with Men) population.
Design and Methods: A stochastic multi-scale model of HIV-1 transmission that integrates within a single framework
the in-host cellular dynamics and their outcomes, patient health states, and sexual contact networks. The model
captures disease state and progression within individuals, and allows for simulation of therapeutic strategies.
Results: Early ART initiation may substantially affect disease spread through a population.
Conclusions: Our model provides a multi-scale, systems-based approach to evaluate the broader implications of
therapeutic strategies.
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Introduction
A complicating aspect of the HIV-1 epidemic is that the virus
spread within human populations and the course of disease
within individuals are intertwined, and governed by multiple
factors that cannot be easily isolated. The disease on both
levels progresses through complex interactions among many
components, which is typical of chronic diseases [1].
Additionally, treatment of HIV-1-infected persons affects not
only their personal health, but also the degree of exposure and
transmission risk to their sexual partners, and consequently the
epidemic dynamics of the entire population. Therefore, a
quantitative analysis of how phenomena on higher scales
emerge from processes on lower scales is crucial to
understanding disease dynamics. Addressing these issues
requires integrated models capable of examining not only
isolated factors, but also their interrelationships across relevant
scales.
Traditional epidemiological modeling is based on two
premises: (1) individuals within a population at any given time
can be either susceptible to disease, infected, or not
susceptible; and (2) the population is fully mixed. It is known
that neither assumption is inadequate for modeling the HIV-1
epidemic; the first one does not account for complexity of
chronic diseases with multiple stages, and the second is a poor
representation of sexual contact patterns [2-26]. Here a
framework combining network-type contact models with more
sophisticated disease models is needed [8,10,27-32].
We introduce a new model of HIV-1 transmission that allows
for assessment of processes on multiple scales of disease,
incorporating an actual sexual contact network, and a detailed
model of disease progression driven by variable within-host
processes, their outcomes, and medical intervention. The
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model is based on an MSM (Men who have Sex with Men)
sexual network documented in Colorado Springs, USA [33],
chosen for several reasons. First, the Colorado Springs sexual
network has been well documented and the network structure
is known. Second, its main core remained largely unchanged
for about 5 years, hence a static network can be assumed.
Third, the HIV status of approximately 70 % of the main core is
known, which allows for model validation under no-treatment
scenario. While simulations in this study have been performed
for an MSM group, the model can be modified for general
populations given that the sexual contact network is known.
Using this model, we investigate the impact of ART initiation
timing on HIV-1 spread in a population. While ART has been
widely accepted as the gold standard of modern care, its timing
is debated [34-39]. The current recommendation by the
Department of Health and Human Services Office of AIDS
Research Advisory Council [40] calls for ART initiation during
the asymptomatic phase, as the number of the CD4+ cells of
the immune system drops below 200 cells/µl. However, several
recent studies provided evidence that initiating therapy earlier
may offer a number of benefits such as decreased severity of
symptoms during the acute infection phase; preservation of the
immune system; reduction of virus diversity, and boosting the
initial host response to viral replication [14,39,41-44]; reduction
of seeding in latent virus reservoirs [44]; lower levels of latently
infected cells [14,45,46]; reduced AIDS and death rates [47].
The downsides of early treatment initiation are the expense,
long-term metabolic effects, treatment fatigue, patients not
being emotionally ready to be adherent. The issue of ART
timing is thus an important example of difficulties associated
with decision-making in complex chronic diseases.
Our overall aim is to evaluate the impact of medical
interventions at the level of individuals, on the spread of
infection across the whole population. Specifically, we
investigate the impact of ART initiation timing on HIV-1 spread
in an MSM population. We demonstrate that our multi-scale,
systems-based approach can be successfully used to evaluate
the broader implications of therapeutic strategies.
Methods
Overall structure of the model
The model describes processes evolving on three scales: (1)
within-host, (2) patient disease progression and state of health,
and (3) disease transmission in a MSM population (Figure 1).
The within-host scale describes dynamics and interactions
between the immune system and the virus for each individual
(Figure 1A). The number of CD4+ cells and the viral load are
computed at a monthly time step, the details of computation
are provided in the section “Within-host models for each health
state”. If the CD4+ count and the viral load satisfy certain
criteria, described in the section “Within-host models for each
health state”, the patient transitions to a new health state.
There is a total of eight health states for each individual, and
the transitions between states take place at the second scale of
the model (Figure 1B). Each individual is placed on a sexual
contact network, which is the third scale of the model (Figure
1C). At each time step, the CD4+ count and the viral load is
assessed for each individual, and his HIV-1 transmissibility is
computed. Based on the transmissibility, his susceptible
partners can become infected and enter the Acute Infection
phase. Their disease histories then progress according to
Figure 1B.
There are several assumptions made in the model. The
sexual contact network is assumed to not change over the
course of simulations. As detailed below, this assumption is
based on a well-documented study by [33] that indicated that
this particular connected component of a larger network
remained unchanged for several years during their study.
Model parameter values have been obtained from several
literature sources, documented in Table 1. Further, percent of
individuals to receive ART was determined a priori. We
conducted three sets of simulations, in which the probability of
any individual to receive ART was set at 0, 0.3 and 1. Zero
probability of receiving ART corresponds to the early period
when ART was not available; probability of 1 is an extreme,
ideal case of everyone receiving ART; and probability of 0.3
represents a more realistic scenario that reflects CDC’s overall
epidemiologic estimate that in the USA about a third of people
with HIV are taking ART regularly [48].
Below we present the model in more detail, starting with
scale 2, namely the patient disease progression and state of
health. This section is followed by description of scale 1, the
within-host processes associated with each health state. These
processes drive transitions between health states. The disease
transmission model in an actual MSM population is then
presented (scale 3). Finally, we discuss the uncertainty and
sensitivity analysis of model outcomes.
Disease progression and health states
States of the disease progression model correspond to
clinically defined disease stages (Figure 1B). Acute infection is
marked by lack of immune responses and uncontrolled viral
replication with high viral loads and relatively large amounts of
genital shedding of HIV-1 [49,50]. Viremia rises rapidly to a
peak, then declines as the immune system starts to exert
partial control [51]. In the chronic asymptomatic phase of
infection the viral load reaches a quasi-steady state called the
set point, which varies between persons and which determines
a relatively constant rate of CD4+ T cell decline. If left
untreated, the onset of clinical AIDS characterized by
opportunistic infections and/or CD4+ T cell count less than 200
cells per µl of blood, takes place 4-10 years after the infection
[52], but the standard of care is the institution of ART before
this point.
Medical treatment significantly extends the duration of the
asymptomatic phase [53]. However, under ART pressure the
virus mutates and eventually becomes resistant to applied
therapy. As a result, the virus load begins to steadily increase,
and the treatment must be modified [54]. ART can be initiated
at any time from acute infection through the asymptomatic
phase in this model. Treatment affects both the viral load and
CD4+ T cell count, therefore altering the transmission
probability [50].
Four consecutive regimens are modeled and assigned
typical rates of response with disease stabilization
Multi-Scale Model of HIV-1 Transmission
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(reconstitution of CD4+ T cells and reduction of viral load to
undetectable levels), and failure over time leading to the next
treatment.
The model allows for simulation of treatment scenarios. If
treatment is initiated in the acute infection phase, patients
move directly to Regimen 1, skipping the asymptomatic phase.
Otherwise patients enter the asymptomatic phase before
Regimen 1 is initiated. The model is easy to modify as more
regimens become available, or as their efficacy changes.
As individuals die of various causes, they enter the Removed
state. Probabilities of transitions to the Removed state
correspond to mortality rates, which vary depending on the
state of health [55,56].
Within-host models for each health state
For each individual we trace two key parameters: the viral
load and the CD4+ cell count. The coupled dynamics of virus
and CD4+ populations drive the transitions between disease
stages (Figure 1B). Figure 1A demonstrates a simulation
sample of viral load evolution during different stages of disease
progression, under two treatment initiation scenarios. The viral
load is typically lower in the case of early ART initiation. Below
we describe the within-host models of viral and CD4+
population dynamics used in generating Figure 1A.
Acute infection.  Healthy individuals are at risk of acquiring
HIV-1 if their sexual partners are infected. Once infected, an
individual enters the acute infection phase. The acute infection
phase is modeled after Perelson and Nelson [57]. Three cell
populations are considered: uninfected CD4+ cells T,
productively infected CD4+ cells T* and free virus V:
dT









The definitions and values of parameters are in Table 1.
Equations (1) are solved numerically in MatLab over 10 weeks
after the infection event, which is a typical duration of the acute
infection phase. At 10 weeks the simulation for the acute
infection stage is terminated and the patient enters the
asymptomatic stage.
Asymptomatic phase.  The asymptomatic phase is treated
as the period where the CD4+ count decays linearly in
untreated patients, with slope m determined by the log-
normally distributed set point logN (9.22, 1.8) [53]. The viral
load remains constant at the set point level, as there is a quasi-
steady state during the chronic asymptomatic phase of
infection [58,59,60]. Transition to Regimen 1 takes place when
the CD4+ count falls below a predetermined threshold.
Treatment regimens.  Clinicians treating patients have
choices between many treatment regimens.  Generally, all
commonly utilized treatment regimens include a combination of
three drugs: two nucleoside reverse transcriptase inhibitors
(NRTIs) and a non-nucleoside reverse transcriptase inhibitor
(NNRTI), or two NRTIs and a protease inhibitor (PI) [40].
 These are considered "first line therapies" with equal efficacy.
 Given the number of medications available, it is usually
Figure 1.  A multi-scale model of HIV-1 transmission.  Within-host models (A) specific to each stage of disease (B) produce
estimates of viral load and CD4+ cell count in every individual. These are key parameters that determine the course of disease, and
dictate when regimens need to be changed. Graphs in (A) are a sample simulation of viral load within one patient, they demonstrate
the differences in viral load in response to changing the timing of ART initiation . Viremia is tempered with ART initiated during the
acute infection phase. Each individual is placed on a sexual network (C) with a distinct structure. The transmissibility is a function of
the CD4+ count that determines the overall health of an individual and therefore the level of sexual activity; and of viral load which
determines the probability of infection in each sexual encounter.
doi: 10.1371/journal.pone.0070578.g001
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possible to have two first line therapies plus a maintenance
regimen that do not overlap in drug resistance patterns, and
patients can use these therapies sequentially without loss of
efficacy if they have failed their first treatment regimen due to
factors such as poor adherence and development of drug
resistance [61].  Following regimens are considered "second
line" and necessarily include re-use of dual NRTIs for which
some resistance mutations have occurred during the first and
second regimens, and therefore have lesser efficacy.  These
are often described as "salvage" or "rescue" regimens [62].
Regimens 1 and 2 of our model correspond to the first line
therapies. For either regimen, each patient is assumed to have
0.47 probability of suppressing the virus, i.e. improving on a
given regimen [61,63], about 87% of these patients experience
Table 1. Model Parameters.
Parameter definition Symbol Value Reference
General Mortality Rate GenMortalityRate 0.0012 [86]
Treatment Failure Rate TreatmentFailureRate 0.0025 [54]
Infected CD4+ count at time zero InitialInfCD4 0  
Viral Load at time zero InitialViralLoad 10-3 viral particles mm-3 [57]
Uninfected CD4+ count at time zero InitialUninfCD4 N (700, 100) cells mm-3 [87]
Death rate of free virus c 2.4 viral particles day-1 [57]
Rate of CD4+ supply from precursors sT 10 cells day-1 mm-3 [57]
Rate of CD4+ proliferation pT 3 10-2 cells day-1 [57]
Death rate of productively infected CD4+ δ 2.4 10-1 cells day-1 [57]
Number of free virus produced by lysing a CD4+ cell N 1200 viral particles [57]
Death rate of uninfected CD4+ dT 2.4 10-1 cells day-1 [57]
Rate constant of CD4+ infection by free virus k 2.4 10-5 cells mm-3 day-1 [57]
Set Point Mp LogN (9.22, 1.8) viral particles mm-3 [53]
Probability of improvement on Regimens 1 and 2 p_EventImpr 0.47 [61]
Probability of CD4+ increase under viral suppression p_EventCD4 0.87 [64]
Probability of improvement on salvage regimen p_EventImprAfterFailure 0.38 [62]
Rate of viral load increase if therapy unsuccessful AddRateVLIncrease 1.6 10-3 viral particles month-1 mm-3 [65]
Rate of CD4+ increase if therapy successful RateCD4Increase 13.33 cells month-1 mm-3 [61]
Rate of viral load decrease if therapy successful  Baseline to undetectable in 2 months [88]
Rate of viral load increase with AIDS RateVLIncreaseAfterFailure 3.4 10-4 viral particles month-1 mm-3 [66]
Rate of CD4+ decrease with AIDS RateCD4DecreaseAfterFailure 5 cells month-1 mm-3 [66]
Rate of CD4+ decline in asymptomatic phase RateCD4DecreaseAsymptom_1, 2, 3, 4, 5 3.02 if Vsp ≤ 0.25 [53]
  3.73 if 0.25 < Vsp ≤ 1.5  
  4.6 if 1.5 < Vsp ≤ 5  
  5.4 if 5 < Vsp ≤ 15  
  6.37 if Vsp > 15  
Mortality rate on ART MortalityRateOnART_1, 2, 3, 4, 5, 6 0.0016 if CD4+ < 25 [67]
  0.0013 if 25 ≤ CD4+ < 50  
  0.003 if 50 ≤ CD4+ < 100  
  0.0041 if 100 ≤ CD4+ < 200  
  0.0032 if 200 ≤ CD4+ < 350  
  0.0031 if CD4+ ≥ 350  
Number of unprotected insertive anal intercourse (UIAI) acts per month NumberUIAI_1, 2, 3, 4, 5, 6, Acute 0.081 if CD4+ ≤ 50 [69]
  1.45 if 50 < CD4+ ≤ 100  
  0.55 if 100 < CD4+ ≤ 200  
  2.69 if 200 < CD4+ ≤ 300  
  1.11 if 300 < CD4+ ≤ 500  
  1.25 if CD4+ > 500  
  1.87 if in Acute Infection phase  
Transmission probability per act of UIAI (transmissibility) TrPr_1, 2, 3, 4, 5, Acute 0.0008 if Viral Load ≤ 0.25 [69]
  0.0088 if 0.25 < Viral Load ≤ 1.5  
  0.0096 if 1.5 < Viral Load ≤ 5  
  0.011 if 5 < Viral Load ≤ 15  
  0.065 if Viral Load > 15  
  0.065 if in Acute Infection phase  
doi: 10.1371/journal.pone.0070578.t001
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restoration of CD4+ counts [64]. The monthly rate of CD4+
increase is about 13.33 cells/mm3 [61].
In patients not responding well to ART, the inability of drugs
to suppress the viral load leads to its steady increase at a
monthly rate of about 0.0016 virions/mm3 [65]. Once the viral
load exceeds 0.2 viral particles/mm3, the regimen has failed,
and the next regimen is initiated.
The salvage regimen is less efficacious than the first two:
viral load suppression probability is 0.38 [62]. Changes in the
CD4+ count and viral load are calculated as before. Failure of
the salvage regimen leads to increased incidence of
opportunistic infections and placement of patients on a
“maintenance” regimen [66,67,68]. While on maintenance
therapy, the viral load increases at a steady rate of 3.4 10-4 viral
particles/mm3/month, while the CD4+ count decreases at 5
cells/mm3/month [66]. Mortality rates of patients on ART, i.e.
probabilities of transitioning to state Removed, are documented
in [55] (Table 1).
Scenarios of interventions tested
HIV-1 spread was simulated over a period of 3 years, with a
monthly time step, i.e. all parameters and transitions from one
health state to another were updated once a month. This time
frame was chosen to satisfy the static network assumption [33],
while allowing sufficient time to study the temporal spread of
disease.
Three scenarios were simulated, testing the effects of
initiating ART at different stages of disease (Figure 1B). The
first scenario corresponds to starting ART when CD4+ T cell
count drops below 200 cells/mm3; this is the only treatment
strategy that has been shown to definitively improve survival in
clinical studies to date. The second scenario corresponds to
current treatment guidelines of starting ART when CD4+ T cells
drop below 350 cells/mm3 and/or the viral load exceeds 50 viral
particles/mm3 during the chronic asymptomatic phase, which is
based on consensus expert opinion [40]. The third scenario is
the debated strategy of initiating ART during acute infection
[35]. The impact of these medical strategies on HIV-1 spread is
analyzed.
Percent of individuals to receive ART was determined a
priori. We conducted three sets of simulations, in which the
probability of any individual in the acute infection stage to
receive ART was set at 0, 0.3 and 1. In case a patient was
chosen to receive ART, he would go through all regimens from
regimen 1 to maintenance (Figure 1B), with ART initiated
according to the scenario being simulated.
Transmission model
Transmission characteristics.  At the level of individuals,
we utilize two key clinical parameters to determine if
transmission takes place: CD4+ T cell count is the key predictor
of health status [40] and therefore of likelihood to engage in
sexual activity [69]; and viral load is an indicator of HIV-1
shedding and risk of transmission during sexual contact
[14,69]. In each contact, transmission occurs with probability
equal to the product of sexual intercourse frequency and risk of
transmission, which are tabulated as functions of CD4+ count
and viral load, respectively (Table 1). Intercourse frequency is
expressed as the number of unprotected insertive anal
intercourse (UIAI) acts per month, which leads to the highest
exposure to HIV-1 [69].
Network of sexual contacts.  The model was validated with
the sexual network originally described by Potterat et al, based
on the analysis of community-wide contact tracing records [33].
The dataset contained 1933 partners, out of which 250
belonged to the largest connected component during the first
five years of the study. We use this component for our
simulations, as it remained virtually unchanged during that time
and we could safely assume that the network was static in the
sense that the edges representing sexual contacts remained
the same. From the 250 subjects, we retained 231 homosexual
and bisexual males and excluded 19 females and heterosexual
males. These 19 individuals were on the periphery of the
network, and their removal did not break the component. The
network structure and information was obtained from Figure 2A
of [33], and re-drawn in Figure 1C with Pajek software [70]. The
distribution of the number of sexual partners in this community
was uneven: most individuals had less than 5 sexual partners,
while two had 20 partners each. At the time of data collection,
about 41% were positively diagnosed for HIV, 34% were
negative and the HIV status of 25% was not known[33,70].
Uncertainty and sensitivity analysis.  Special numerical
methods are needed to analyze the behavior of complex
mathematical models such as ours, as well as the effect of
model parameters on its output. Uncertainty analysis assesses
the variability of model outcomes due to uncertainty in
estimation of input parameters, while sensitivity analysis
extends the uncertainty analysis by evaluating the importance
of input parameters [71]. Both are powerful tools designed to
investigate the behavior of complex models with uncertain input
parameters [72].
We used the Latin Hypercube Sampling (LHS) scheme, one
of the most computationally efficient methods for uncertainty
analysis [72,73,74]. In this method, input parameters are
treated as random variables, each with its own probability
distribution function. Parameter values are chosen randomly
from their respective stratified distribution functions; input
vectors are thus created containing parameter values for model
simulations. The model is then run several times, each time
with a new set of input parameter values, and its output is
recorded. This completes the uncertainty analysis; next the
sensitivity analysis is performed, here with factor prioritization
by reduction of variance used to rank the importance of
parameters to model outcomes. This method is applied when
the relationship between the outcome and input parameters is
highly nonlinear, which is the case here [75]. Sensitivity indices
produced for each input parameter are interpreted as the
proportion of total output variance attributable to the given
parameter [72]. We implemented the analysis with MatLab-
based SaSAT software [75].
Results
Epidemiology
The temporal propagation of disease for varying probability
of receiving ART, pART = 0, 0.3, 1 is shown in Figure 2. The
Multi-Scale Model of HIV-1 Transmission
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case of pART = 0 refers to years before introduction of ART; pART
= 0.3 represents an assumption that currently about 30% of
infected individuals receive ART; pART = 1 represents an ideal
situation where ART is received by all infected individuals.
In each case, all three scenarios of ART initiation timing are
tested, with 100 simulations performed for each scenario. At
time zero, one of the two individuals with the highest number of
sexual contacts (twenty) is infected, while the rest of the
population is healthy and therefore susceptible to disease.
When no ART is available to anyone (Figure 2A), all three
scenarios converge into the same curve, as expected. At the
end of the 3-year simulation, about 8% of the population is
infected. With pART=0.3 and ART initiation in the acute infection
phase, at 3 years less than 7% of population are infected
(Figure 2B); with pART=1, about 3% are infected (Figure 2C).
The reduction of 0.01 in fraction infected at the end of the
simulation (Figure 2B, p_ART=0.3) translates into a maximum
of about 7.5 patient-years over 3 years. This number would
then translate into a respective reduction in ART medication for
the whole population. Collectively, these results indicate that
significant reduction in the fraction of infected individuals could
be achieved by initiating ART as early as possible, and by
administering it to as many individuals as possible.
The results also indicate that initiating ART at CD4+ T cell
counts of 200 versus 350 cells/mm3 demonstrates minimal
difference in the spread of HIV-1. For pART=1 (Figure 2C), the
difference is about 8.4 versus 8.1% at 3 years, while ART
initiation during acute infection markedly decreases the fraction
of infected persons (to about 3.5% at 3 years). A similar picture
arises in pART=0.3 (Figure 2B). Therefore, modifying ART
initiation threshold during chronic infection (first two scenarios)
had a small effect at the population level.
The number of patients infected at time zero is an important
factor in the dynamics of disease spread. We ran a simulation
with a larger initial number (about 10% of entire population) of
infected individuals (Figure 3). In this case a much higher
fraction of individuals are infected at 3 years in all scenarios, as
expected. Similarly to the case of only one highly connected
individual infected at time zero (Figure 2C), ART initiation
during acute infection blunts the spread of the virus compared
to later ART initiation (10.8% for early ART versus 13.5% and
13.7% for ART starting at CD4+ T cell counts of 200 and 350).
Notably, for both initial conditions, there is an early phase of
Figure 2.  Temporal propagation of disease within 3 years for three scenarios of ART initiation timing.  In all simulations a
patient with 20 sexual partners is infected at time zero. Three scenarios of ART initiation are simulated: at the CD4+ cutoff below 200
cells/mm3, 350 cells/mm3 and in acute infection phase. (A) No one receives ART; (B) about 30% of infected individuals receive ART;
(C) all infected individuals receive ART.
doi: 10.1371/journal.pone.0070578.g002
Multi-Scale Model of HIV-1 Transmission
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rapid HIV-1 spread that is particularly suppressed by early
ART, likely due to aggressive early spread of disease by
contagious persons with acute infection (high viral loads).
Thus, ART initiation during the acute infection phase
significantly alters the course of the epidemic, and results in
much lower fractions of infection in the long term.
To test the model predictions we simulated a situation with
no ART available to anyone, and with both highly connected
individuals infected at time zero (Figure 4). This situation is
likely to have arisen in Colorado Springs in the mid 80s, when
no ART was available. Simulations indicate that at 5 years the
fraction of infected individuals averaged to about 40%, which is
in excellent agreement with data from Colorado Springs where
41% are HIV positive [33].
Our results also agree with the conclusions of a recent study
by Granich and co-workers [36] who looked at possible
outcomes of universal HIV testing with immediate initiation of
ART. Their model was based on general population data from
South Africa. Similarly to our results (Figure 4), the authors
predicted a 6% increase in new infection cases in the course of
a year in a scenario without ART. They also modeled a
scenario in which individuals would be tested on a yearly basis
and, if tested positive, would immediately be offered ART. In
this scenario not all newly diagnosed individuals would still be
in the acute infection phase and many would have progressed
into the asymptomatic phase, however the results generally
agree with our conclusions. Our model predicts a 56% drop at
3 years in the fraction of infected individuals who are offered
ART in the acute infection phase (Figure 2C) as opposed to
those who are not offered ART (Figure 2A). Granich and co-
workers calculated a 45% difference in HIV prevalence
between no ART and immediate ART initiation upon positive
HIV test scenario. This re-affirms that starting ART in the acute
infection phase is likely to be highly efficient in curbing the
spread of disease.
Uncertainty and sensitivity analysis
Uncertainty and sensitivity analysis were conducted for all
three scenarios of ART timing initiation; for each scenario 200
simulations were performed. The model output is the fraction of
infected individuals; parameter values are sampled from
respective probability distributions (Table 2). The results are
shown in Table 3. In both scenarios of late ART initiation, the
parameter responsible for most of disease spread variability is
Mp, the viral set point; it accounts for 94% and 86.6% of model
output variability in cases of ART initiation below CD4+ count of
200 cells/m3 and 350 cells/m3 respectively. The contribution of
the rest of model parameters is negligible (less than 2% each
in either scenario).
Figure 3.  A cluster containing 10% of the population is infected at time zero, all infected individuals receive ART.  ART
initiation scenarios are as in Figure 2. The simulation is performed to test the response of the model to an increase of the number of
patients infected at time zero.
doi: 10.1371/journal.pone.0070578.g003
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In the case of ART initiation in the acute infection phase, the
viral set point remains the most influential parameter, albeit
with a much lower sensitivity index at 19.1%. It appears that
early ART initiation blunts the large effect of the viral set point.
Its contribution to the output variability is balanced by four other
parameters: p_eventCD4, the probability of CD4+ increase
under viral suppression (7.7%); MortalityRateOnTreatment_3,
the mortality rate while on ART, with CD4+ count between 50
and 100 cells/mm3 (6.5%); and the number of UIAI acts per
month with the CD4+ count above 500 cells/mm3 (6.9%) and
during the acute infection phase (6.4%). The contribution of
each of the remaining parameters to the spread of disease is
below 5%.
The viral set point is a major indicator of the course of
disease following the end of the acute infection phase, and is
highly correlated with the CD4+ count decay in the
asymptomatic phase and with viral activity [53]. So, it is not
surprising that in cases of late ART initiation when the disease
develops according to its natural pace for an extended duration
of time, the viral set point plays a major role. The CD4+ count is
a general indicator of an individual’s health state and of sexual
activity [69] (Table 1), hence the significance of p_eventCD4.
The importance of UIAI acts per month, particularly during
acute infection, is in accord with evidence that as high as 48%
of transmission cases take place during the acute infection
phase [76], and with our results demonstrating the difference
that early ART initiation makes in disease propagation (Figure
2).
Discussion
Multi-scale modeling provides a possibility for studying
relationships between processes on different scales within the
same framework. The integration of models at microbiologic,
individual host, and population scales offers a medium to
examine how the effects of individual interventions scale
across the entire framework. Our model takes this approach to
capture how the dynamics of disease progression in individuals
affect HIV-1 spread within an MSM population. This allows for
simulation of medical interventions, such as varying treatment
strategies, drug efficacies, and prevention strategies. For
example, this modeling framework would be suited for
evaluating the impact of interventions such as the effect of ART
initiation upon detection of HIV during once-yearly testing and
treatment, behavioral changes, implementation of a vaccine
that reduces viral load without preventing infection, and
modification of community-wide treatment recommendations.
We have tested the model in simulations of altering the ART
initiation timing, a topic of current controversy [34,35,39]. The
problem of treatment initiation timing is an excellent example of
intricacies of decision-making in complex diseases that evolve
on multiple scales. On the one hand, deferring ART would
delay the development of drug resistance and preserve
therapeutic options, reduce the accumulated effects of drug
toxicity, and conserve potentially limited resources. On the
other hand, the longer period off treatment could render
infected persons more contagious and allow greater spread of
virus. Our simulations, utilizing several biologically observed
parameters, have addressed this latter factor by estimating
how different interventions on the microbiologic scale affect
population-wide spread of HIV-1. These simulations suggest
that altering the timing of ART initiation during chronic infection
has a minimal impact on community transmission (suggesting
that patients can be saved the misery of the heavy ART
medication, and society the costs of additional ART by not
treating at 350 CD4+ cells/mm3), but that routinely starting ART
during acute infection could have a major role in reducing
spread.
Figure 4.  The two individuals with the highest number of sexual partners (20) are infected at time zero.  No one receives
ART. The simulation is performed to test the response of the model to the impact of highly connected individuals.
doi: 10.1371/journal.pone.0070578.g004
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Table 2. Parameter distributions for uncertainty and sensitivity analysis.
ParameterName Distribution1 Argument 12 Argument 2
GeneralMortalityRate U 5.75 ⋅ 10-5 1.73 ⋅ 10-4
TreatmentFailureRate U 0 5 ⋅ 10-3
CD4AsymptomPhaseCutoff D 2 ⋅ 102  
InitialUninfCD4 N 7 ⋅ 102 102
InitialInfCD4 D 0.00  
InitialViralLoad U 5 ⋅ 10-1 5 ⋅ 106
TrPr_Acute U 4.4 ⋅ 10-2 8.6 ⋅ 10-2
TrPr_1 U 5.4 ⋅ 10-4 10-3
TrPr_2 U 5.9 ⋅ 10-3 1.2 ⋅ 10-2
TrPr_3 U 6.4 ⋅ 10-3 1.3 ⋅ 10-2
TrPr_4 U 7.4 ⋅ 10-3 1.5 ⋅ 10-2
TrPr_5 U 1.2 ⋅ 10-2 2.4 ⋅ 10-2
NumberUIAI_1 G 7.1 ⋅ 10-1 2.65
NumberUIAI_2 G 7.1 ⋅ 10-1 1.15
NumberUIAI_3 G 7.1 ⋅ 10-1 2.05
NumberUIAI_4 G 7.1 ⋅ 10-1 7.8 ⋅ 10-1
NumberUIAI_5 G 7.1 ⋅ 10-1 3.80
NumberUIAI_6 G 7.1 ⋅ 10-1 1.57
NumberUIAI_7 G 7.1 ⋅ 10-1 1.77
MortalityRateOnTreatment_1 U 8 ⋅ 10-4 2.4 ⋅ 10-3
MortalityRateOnTreatment_2 U 6.5 ⋅ 10-4 1.9 ⋅ 10-3
MortalityRateOnTreatment_3 U 1.5 ⋅ 10-3 4.5 ⋅ 10-3
MortalityRateOnTreatment_4 U 2.5 ⋅ 10-3 6.1 ⋅ 10-3
MortalityRateOnTreatment_5 U 1.6 ⋅ 10-3 4.8 ⋅ 10-3
MortalityRateOnTreatment_6 U 1.5 ⋅ 10-3 4.6 ⋅ 10-3
p_eventImpr U 10-1 6 ⋅ 10-1
p_eventCD4 U 5 ⋅ 10-1 1.00
AddRateVLDecrease U 10-3 3 ⋅ 10-3
RateCD4Increase U 6.67 20.0
AddRateVLIncrease U 8 ⋅ 10-4 2.4 ⋅ 10-3
c U 1.20 3.60
sT U 1.5 ⋅ 102 4.5 ⋅ 102
pT U 4.5 ⋅ 10-1 1.35
Tmax U 7.5 ⋅ 102 2.25 ⋅ 102
dT U 3 ⋅ 10-1 9 ⋅ 10-1
k U 3.6 ⋅ 10-4 1.1 ⋅ 10-3
delta U 3.60 1.08 ⋅ 101
N U 6 ⋅ 102 1.8 ⋅ 103
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These results are encouraging support for our model, in light
of several clinical observations regarding the
immunopathogenesis of HIV-1 infection. Potent ART regimens
developed since the mid-1990s are successful at suppressing
viral replication within infected persons, thereby halting or
reversing disease progression and extending the asymptomatic
phase of infection in association with reducing viral replication
as measured by viral load [14,15]. Viral replication is also a key
factor in host-host transmission of HIV-1; and viral load is a
strong predictor of the risk of transmission per exposure. Acute
infection is characterized by extremely high viral loads and
virus shedding in genital secretions [49,50], and this probably
explains the observation that acutely-infected individuals
contribute disproportionately to HIV-1 spread, with an 8 to 20
fold increase in odds of transmission per coital act [14]. It is
estimated that as high as 48% of all cases of HIV-1
transmission occur when the transmitting host is within the first
five months of being infected [76]. Thus, our model yields
results that are compatible with the biological principles of
HIV-1 infection, suggesting that suppression of viral replication
with ART in the early stage of infection mediates a
disproportionate effect in preventing transmission compared to
starting ART during chronic infection. This is consistent with a
hypothesized benefit of early treatment in attenuating the
spread of HIV-1 [14,26,49,50,76,77,78]. Several recent studies
also concluded that universal and if possible early
administration of ART is a powerful way to prevent the spread
of the disease [36,37,79]
A major obstacle to early implementation of ART is the timely
diagnosis of early HIV-1 infection, primarily due to absence of
specific and recognizable symptoms. To aggravate the
problem, routine HIV-1 antibody tests remain negative for
several weeks past initial infection. More sensitive, virus-
specific tests such as HIV p24 antigen ELISA and HIV nucleic
acid amplification assays are available but they are expensive
and prone to high (1%) false-positive rates.
Strategies however can be and are being developed to meet
these challenges. The blood-banking industry routinely
combines antibody and HIV RNA tests, such as initial
screening of specimens using antibody testing followed by
blood pooling prior to HIV RNA testing. These strategies are
Table 2 (continued).
ParameterName Distribution1 Argument 12 Argument 2
Mp LN 9.22 1.80
p_eventImprAfterFailure U 0.00 5 ⋅ 10-1
RateVLIncreaseAfterFailure U 1.7 ⋅ 10-4 5.1 ⋅ 10-4
RateCD4DecreaseAfterFailure U 2.50 7.50
RateCD4DecreaseAsymptom_1 U 1.51 4.53
RateCD4DecreaseAsymptom_2 U 1.87 5.60
RateCD4DecreaseAsymptom_3 U 2.30 6.90
RateCD4DecreaseAsymptom_4 U 2.70 8.10
RateCD4DecreaseAsymptom_5 U 3.19 9.56
p_ART N 4 ⋅ 101 10
1. U(Uniform), N(Normal), G(Gamma), D(Deterministic)
2. For Uniform distribution, Argument1 is the minimum, Argument 2 is the maximum of the range
For Normal and LogNormal distributions, Argument1 is the mean, Argument 2 is the standard deviation
For Gamma distribution, Argument1 is the shape parameter, Argument 2 is the scale parameter
doi: 10.1371/journal.pone.0070578.t002
Table 3. Sensitivity indices (above 0.05 in bold) representing proportion of total variance attributable to the given parameter.
Parameter Scenario 1: Treatment start at CD4≤200 Scenario 2: Treatment start at CD4≤350 Scenario 3: Treatment start in Acute Infection
Mp 0.94 0.86 0.19
p_eventCD4 0.000066 0.0002 0.077
NumberUIAI_5 0.002 0.006 0.069
MortalityRateOnTreatment_3 0.005 0.002 0.065
NumberUIAI_6 0.002 0.01 0.064
doi: 10.1371/journal.pone.0070578.t003
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being extended to clinical testing in Swiss, US and Indian
studies.
Interestingly, acute HIV-1 infection is not rare in clinical-
testing groups [80,81,82], especially in hyperendemic regions
such as India and Malawi [83,84]. Hence, a combination of
accurate testing strategies and screening/tracing programs
such as for instance “network notification” whereby partners of
HIV-positive individuals are notified of their need for HIV testing
[85] could potentially dramatically increase the level of acute
infection detection.
A potential development of the model would be the use of
dynamic network models from following MSM or mixed
communities over time. Other macro-scale issues that could be
incorporated include the cost of ART and limited distribution of
drugs in resource-poor locales. At the individual scale,
adherence to therapy and host-specific microbiologic factors
could be included. At the microbiologic scale, designating viral
loads as a single determining factor with stochastic variation in
set-point is an oversimplification of complex processes. Further
defining lower scales such as HIV-1 evolution and mutation,
host immunity, metabolism and genetic background, may be
important to provide more accurate predictions of ART and
vaccine efficacy, and drug toxicity.
Ultimately, the goal is for medical decision-making to
significantly benefit from utilization of multi-scale models. Such
models are particularly needed for chronic infectious diseases
such as HIV-1 infection, where individual medical interventions
are likely to have effects on the pattern of the epidemic, and
where public policy decisions are likely to affect individuals.
Thus a systems-based approach is crucial to gauge and predict
benefits and risks across all scales. Our proposed model has
potential applications where such multi-scale considerations
are important, as we have demonstrated by examining an
ongoing unresolved clinical question regarding timing of ART
initiation.
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